Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

________________________

 

Washington, D.C. 20549

_____________________

 

FORM 6-K

_____________________

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of November 2024

Commission File Number: 001-37835

________________________________________

 

Indivior PLC

________________________________________

 

10710 Midlothian Turnpike, Suite 125

North Chesterfield, Virginia 23235

 

(Address of principal executive office)

 

_______________________________

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

 

Form 20-F ☒ Form 40-F ☐

 

 

 

 

 

 

 

 

 

 

 

EXHIBIT INDEX

 

Exhibit No.	Description of Exhibit
99.1	Announcement sent to the London Stock Exchange on November 22, 2024, titled “Indivior to Participate in Upcoming Investor Event”.

 

 

 

 

 

 

 

SIGNATURES

 

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

 

	Indivior PLC
Date: November 22, 2024	/s/ Kathryn Hudson
	Name: Kathryn Hudson
	Title: Company Secretary

 

 

Exhibit 99.1

 

 

Indivior To Participate in Upcoming Investor Event

 

Slough, UK, and Richmond, VA, November 22, 2024 – Indivior PLC (NASDAQ/LSE: INDV) today announced that it will participate in the following investor event:

 

●

Piper Sandler 36th Annual Healthcare Conference – New York City, NY

 

Mark Crossley, Chief Executive Officer, and Ryan Preblick, Chief Financial Officer, will host 1x1 / group meetings on Tuesday, December 3rd. Mark Crossley will also participate in a fireside discussion on Tuesday, December 3rd at 10:00 a.m. US ET. Interested investors should contact their Piper Sandler representative to schedule a meeting. The fireside chat will be publicly available and can be viewed using the following weblink:

 

https://event.webcasts.com/starthere.jsp?ei=1697247&tp_key=c34d7b2697 

               

 

 

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD), overdose and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.

 

 

Contact:

Jason Thompson

Vice President, Investor Relations

Tel: [phone] or [e-mail]

 

Tim Owens

Director, Investor Relations

Tel: [phone] or [e-mail]

 

###

 

---